Improved time to treatment failure with an intermittent oxaliplatin strategy: Results of CONcePT

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1172-1178

  Hochster, Howard ^a   Grothey, A ^b   Hart, L ^c   Rowland, K ^d   Ansari, R ^e   Alberts, S ^f   Chowhan, N ^g   Ramanathan, R K ^h   Keaton, M ⁱ   Hainsworth, J D ^j   Childs, B H ^e  

^a YALE CANCER CENTER   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c Drug Development Program Florida Cancer Specialists   (United States)

^d Carle Cancer Center   (United States)

^e Michiana Hematology Oncology ^*  (United States)

^f MAYO CLINIC   (United States)

^g Floyd Memorial Cancer Center of Indiana   (United States)

^h HonorHealth and the Scottsdale Lincoln Health Network   (United States)

ⁱ Augusta Oncology Associates   (United States)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

more..

Author keywords

Bevacizumab; Calcium and magnesium salts; Colorectal cancer; Drug induced neurotoxicity; FOLFOX; Intermittent

Indexed keywords

GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIPLATIN; PLACEBO; ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; THROMBOCYTOPENIA; TIME TO TREATMENT; TIME TO TREATMENT FAILURE; TREATMENT DURATION; VOMITING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM GLUCONATE; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MAGNESIUM SULFATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS;

EID: 84903895266     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu107     Document Type: Article

References (20)

1. NCCN Clinical Practice Guidelines in Oncology for Colon Cancer. V.1.2011.
2. Goldberg RM. N9741: a phase III study comparing irinotecan to oxaliplatincontaining regimens in advanced colorectal cancer. Clin Colorectal Cancer 2002; 2: 81.
3. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
4. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
5. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 129a. Abstr 512.
6. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
7. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019. Erratum in: J Clin Oncol 2008; 26: 3110; J Clin Oncol 2009; 27: 653.
8. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
9. Gamelin L, Boisdron-Celle M, Morel A et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-1189.
10. Ali BH. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic Clin Pharmacol Toxicol 2010; 106: 272-279.
11. de Gramont A, Buyse M, Abrahantes JC et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 3224-3229.
12. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24: 394-400.
13. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005; 5(suppl 1): S38-S46.
14. Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 2009; 6: 207-218.
15. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events Version 3.0.
16. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572. Erratum in: N Engl J Med 2010; 363: 2573.
17. Hochster H, Grothey A, Shpilsky A et al. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Presented at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, USA; January 25-27, 2008; Abstr 280.
18. Grothey A, Nikcevich DA, Sloan JA et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29: 421-427.
19. Knijn N, Tol J, Koopman M et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47: 369-374.
20. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12: 38-50.